These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

448 related articles for article (PubMed ID: 33291334)

  • 1. New Carbapenemase Inhibitors: Clearing the Way for the β-Lactams.
    Vázquez-Ucha JC; Arca-Suárez J; Bou G; Beceiro A
    Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33291334
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-β-Lactamase Inhibitor Combinations.
    Zhanel GG; Lawrence CK; Adam H; Schweizer F; Zelenitsky S; Zhanel M; Lagacé-Wiens PRS; Walkty A; Denisuik A; Golden A; Gin AS; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2018 Jan; 78(1):65-98. PubMed ID: 29230684
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-Lactamases and β-Lactamase Inhibitors in the 21st Century.
    Tooke CL; Hinchliffe P; Bragginton EC; Colenso CK; Hirvonen VHA; Takebayashi Y; Spencer J
    J Mol Biol; 2019 Aug; 431(18):3472-3500. PubMed ID: 30959050
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Infectious diseases caused by carbapenemase-producing Enterobacteriaceae--a particular challenge for antibacterial therapy].
    Stock I
    Med Monatsschr Pharm; 2014 May; 37(5):162-72; quiz 173-4. PubMed ID: 24908928
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carbapenemase Inhibitors: Updates on Developments in 2021.
    Bou Zerdan M; Al Hassan S; Shaker W; El Hajjar R; Allam S; Bou Zerdan M; Naji A; Zeineddine N
    J Clin Med Res; 2022 Jul; 14(7):251-259. PubMed ID: 35974805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolving resistance landscape in gram-negative pathogens: An update on β-lactam and β-lactam-inhibitor treatment combinations for carbapenem-resistant organisms.
    Koenig C; Kuti JL
    Pharmacotherapy; 2024 Aug; 44(8):658-674. PubMed ID: 38949413
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel β-lactam-β-lactamase inhibitor combinations: expectations for the treatment of carbapenem-resistant Gram-negative pathogens.
    Karaiskos I; Galani I; Souli M; Giamarellou H
    Expert Opin Drug Metab Toxicol; 2019 Feb; 15(2):133-149. PubMed ID: 30626244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meropenem-Vaborbactam Activity against Carbapenem-Resistant
    Castanheira M; Doyle TB; Kantro V; Mendes RE; Shortridge D
    Antimicrob Agents Chemother; 2020 Jan; 64(2):. PubMed ID: 31712207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Citrobacter freundii resistant to novel β-lactamase inhibitor combinations and cefiderocol, co-producing class A, B and D carbapenemases encoded by transferable plasmids.
    Riccobono E; Salvetti S; Coppi M; Montenora I; Di Pilato V; Rossolini GM
    J Antimicrob Chemother; 2023 Jul; 78(7):1677-1682. PubMed ID: 37207353
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical Characterization of QPX7728, a New Ultrabroad-Spectrum Beta-Lactamase Inhibitor of Serine and Metallo-Beta-Lactamases.
    Tsivkovski R; Totrov M; Lomovskaya O
    Antimicrob Agents Chemother; 2020 May; 64(6):. PubMed ID: 32152086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MULTIRESISTANT BACTERIA].
    Bedenić B; Sardelić S; Ladavac M
    Acta Med Croatica; 2015 Sep; 69(3):211-6. PubMed ID: 29077379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vaborbactam: Spectrum of Beta-Lactamase Inhibition and Impact of Resistance Mechanisms on Activity in Enterobacteriaceae.
    Lomovskaya O; Sun D; Rubio-Aparicio D; Nelson K; Tsivkovski R; Griffith DC; Dudley MN
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28848018
    [TBL] [Abstract][Full Text] [Related]  

  • 13. OXA-48-Like β-Lactamases: Global Epidemiology, Treatment Options, and Development Pipeline.
    Boyd SE; Holmes A; Peck R; Livermore DM; Hope W
    Antimicrob Agents Chemother; 2022 Aug; 66(8):e0021622. PubMed ID: 35856662
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of a Cyclic Boronic Acid β-Lactamase Inhibitor (RPX7009) with Utility vs Class A Serine Carbapenemases.
    Hecker SJ; Reddy KR; Totrov M; Hirst GC; Lomovskaya O; Griffith DC; King P; Tsivkovski R; Sun D; Sabet M; Tarazi Z; Clifton MC; Atkins K; Raymond A; Potts KT; Abendroth J; Boyer SH; Loutit JS; Morgan EE; Durso S; Dudley MN
    J Med Chem; 2015 May; 58(9):3682-92. PubMed ID: 25782055
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Carbapenem-resistant Gram-negative pathogens in a German university medical center: Prevalence, clinical implications and the role of novel β-lactam/β-lactamase inhibitor combinations.
    Katchanov J; Asar L; Klupp EM; Both A; Rothe C; König C; Rohde H; Kluge S; Maurer FP
    PLoS One; 2018; 13(4):e0195757. PubMed ID: 29649276
    [TBL] [Abstract][Full Text] [Related]  

  • 16. WCK 4234, a novel diazabicyclooctane potentiating carbapenems against Enterobacteriaceae, Pseudomonas and Acinetobacter with class A, C and D β-lactamases.
    Mushtaq S; Vickers A; Woodford N; Livermore DM
    J Antimicrob Chemother; 2017 Jun; 72(6):1688-1695. PubMed ID: 28333319
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure and Mechanism-Guided Design of Dual Serine/Metallo-Carbapenemase Inhibitors.
    Chen C; Oelschlaeger P; Wang D; Xu H; Wang Q; Wang C; Zhao A; Yang KW
    J Med Chem; 2022 Apr; 65(8):5954-5974. PubMed ID: 35420040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Assessing the Potency of β-Lactamase Inhibitors with Diverse Inactivation Mechanisms against the PenA1 Carbapenemase from
    Nukaga M; Yoon MJ; Taracilia MA; Hoshino T; Becka SA; Zeiser ET; Johnson JR; Papp-Wallace KM
    ACS Infect Dis; 2021 Apr; 7(4):826-837. PubMed ID: 33723985
    [No Abstract]   [Full Text] [Related]  

  • 19. Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli.
    Zhanel GG; Golden AR; Zelenitsky S; Wiebe K; Lawrence CK; Adam HJ; Idowu T; Domalaon R; Schweizer F; Zhanel MA; Lagacé-Wiens PRS; Walkty AJ; Noreddin A; Lynch Iii JP; Karlowsky JA
    Drugs; 2019 Feb; 79(3):271-289. PubMed ID: 30712199
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Kaushik A; Ammerman NC; Lee J; Martins O; Kreiswirth BN; Lamichhane G; Parrish NM; Nuermberger EL
    Antimicrob Agents Chemother; 2019 Mar; 63(3):. PubMed ID: 30642943
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.